Horizon Therapeutics (HZNP) Tops Q2 EPS by 19c

Horizon Therapeutics (NASDAQ: HZNP) reported Q2 EPS of $1.20, $0.19 better than the analyst estimate of $1.01. Revenue for the quarter came in at $945 million versus the consensus estimate of $897.62 million.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Legence Corp (LGN) PT Raised to $130 at Tigress Financial Partners
• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance